 CONCORD, Calif.--BUSINESS WIRE--Cerus Corporation Nasdaq: CERS today announced the oral presentation of a clinical study: Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study, presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pmEST. This presentation reviews data on the efficacy 